GenoMed, Inc. finalizes Letter of Intent with DW Coordinating Center to acquire Caucasian Samples
January 18, 2002--GenoMed Inc.--(“the Company” or “GenoMed”) (National Quotation Bureau’s Pink Sheets Symbol: GMED), a St. Louis, Missouri based medical genomics biotechnology company, announced today that it has signed a Letter of Intent with DW Coordinating Center (DWCC; website: www.dwccenter.com) to acquire Caucasian samples for fifty common, serious diseases.
DWCC is a global contract research organization with operations in Russia and Eastern Europe. DWCC will obtain blood samples from patients with common diseases, such as high blood pressure, heart attack, stroke, and various cancers. DWCC uses FDA approved practices of sample collection, including informed patient consent, and has a sophisticated quality control system. DWCC has conducted clinical research since 1989 for pharmaceutical and biotechnology
companies, and for research institutes, including Aventis, Glaxo SmithKline, Pfizer, CV Therapeutics, and the National Institutes of Health. Since 1989, DWCC has recruited over 19,000 patients for clinical trials.
Dr. David Moskowitz, Chairman and Chief Medical Officer of GenoMed, stated, "First and foremost we are very pleased to have established this relationship with DWCC. I am confident that the Company’s relationships with organizations such as DWCC will provide the Company with the samples that it needs to generate a tremendous amount of disease gene data from a variety of ethnic groups. Over the next 12-24 months, the Company will score millions of genotypes from these samples and work diligently to identify the associations within each specific ethnic group that cause these serious diseases. Obviously, we believe that this data will be of substantial importance to the healthcare industry, and be a valuable asset to the Company from a business standpoint.”
About GenoMed
GenoMed was founded with the sole purpose of translating knowledge of disease genes into better patient outcomes as rapidly and as safely as possible. The Company's business model specifically links improved patient outcomes to Company revenues through clinical treatment and genetic diagnoses of diseases.
About DWCC
DW Coordinating Center (DWCC) has been a full service Clinical Research Organization (CRO) conducting multinational clinical trials in Eastern Europe and Russia since its foundation in 1989. Now headquartered in Los Altos, California, the company has collaborative partners in Russia (St. Petersburg, Moscow and Siberia), Georgia, Belarus, Bulgaria, the Czech Republic, France, Hungary, Latvia, Poland, Slovakia, and Ukraine. DWCC combines international business practices, modern equipment and the latest data transmission technology with the expertise of Eastern European investigators. This enables DWCC to provide the highest-quality services to its clients at the lowest possible cost. In multinational clinical trials, DWCC consistently had the highest recruitment rates of all participating CROs. BioCollections Worldwide, Inc., located in Miami, Florida, has developed an extensive network of physician and patient contacts throughout the world. BioCollections Worldwide uses informed patient consent and other standard, approved protocols in the collection of blood samples for DNA analysis.
For additional information please visit www.genomedics.com and/or contact Craig Hall @ (941) 366-6677 or email at chall@floridafunds.com for a GenoMed investor package.
. |
